Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1987 Mar;126(3):546-60.

Immunoreactivity for Leu-7 in neurofibrosarcoma and other spindle cell sarcomas of soft tissue

Immunoreactivity for Leu-7 in neurofibrosarcoma and other spindle cell sarcomas of soft tissue

P E Swanson et al. Am J Pathol. 1987 Mar.

Abstract

Monoclonal antibodies to Leu-7 have been reported to recognize a constituent of myelin-associated glycoprotein. Because of this, the authors studied 20 cases of neurofibrosarcoma (NFS), 7 of leiomyosarcoma (LMS), 3 of fibrosarcoma (FS), 8 of malignant fibrous histiocytoma (MFH), 5 of monophasic spindle cell synovial sarcoma (MSS), 5 of neurilemmoma, and 5 of neurofibroma for Leu-7 reactivity, to determine its utility in differential diagnosis. Selected examples of each tumor type were also studied ultrastructurally. Leu-7 was compared with the expression of S-100 protein, myelin basic protein, desmin, cytokeratin, and epithelial membrane antigen in the 43 neoplasms. Fifteen examples of NFS, 2 of LMS, and 2 of MSS were Leu-7+; 2 neurofibromas and 4 neurilemmomas also demonstrated reactivity with this antibody. In contrast, all cases of FS and MFH were Leu-7-. Synovial sarcomas could be effectively separated from NFS by reactivities for cytokeratin and epithelial membrane antigen in the former, but not the latter, lesions. However, LMSs and NFSs demonstrated significant immunocytochemical overlap, including shared positivity for S-100, desmin, and myelin basic protein in several cases. These results suggest that Leu-7 has restricted utility in immunohistochemical diagnosis, and must be utilized only in concert with other antigens. Moreover, it would appear that in selected instances, smooth-muscle and neurogenic sarcomas must be separated on the basis of clinical, histopathologic, and ultrastructural features alone.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Cancer. 1974 Mar;33(3):888-97 - PubMed
    1. Lab Invest. 1983 Sep;49(3):299-308 - PubMed
    1. Nature. 1983 Nov 24-30;306(5941):376-8 - PubMed
    1. Cancer. 1984 Mar 1;53(5):1190-3 - PubMed
    1. Arch Dermatol. 1984 Feb;120(2):210-3 - PubMed

Publication types

Substances

LinkOut - more resources